Safety and preliminary efficacy from the phase 1 portion of MasterKey-01: A First-in-human dose-escalation study to determine the recommended phase 2 dose (RP2D), pharmacokinetics (PK) and preliminary antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients (pts) with advanced solid malignancies.

Alison M. Schram,Jordi Rodon Ahnert,Manish R. Patel,Shekeab Jauhari,Jasgit C. Sachdev,Viola W. Zhu,Patricia LoRusso,Danny Nguyen,Xiuning Le,Matthew OConnor,Nigel J. Waters,Carl Cook,Karsten Witt,Rachel Humphrey,Pasi A. Jänne,Erika Hamilton

Safety and preliminary efficacy from the phase 1 portion of MasterKey-01: A First-in-human dose-escalation study to determine the recommended phase 2 dose (RP2D), pharmacokinetics (PK) and preliminary antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients (pts) with advanced solid malignancies.

2021

Alison M. Schram
Jordi Rodon Ahnert
Manish R. Patel
Shekeab Jauhari
Jasgit C. Sachdev
Viola W. Zhu
Patricia LoRusso
Danny Nguyen
Xiuning Le
Matthew OConnor
Nigel J. Waters
Carl Cook
Karsten Witt
Rachel Humphrey
Pasi A. Jänne
Erika Hamilton

3086Background: BDTX-189 is an orally available, ATP-competitive and irreversible inhibitor directed against families of allosteric HER2 and EGFR oncogenic mutations. In preclinical studies BDTX-18...

Keywords:

dose escalation
antitumor activity
Medicine
first in human
in patient
Allosteric regulation
Pharmacokinetics
Pharmacology
ErbB

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations